Search hospitals > Florida > Orlando
AdventHealth Orlando
Claim this profileOrlando, Florida 32803
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Leukemia
Conducts research for Tumors
Conducts research for Non-Small Cell Lung Cancer
658 reported clinical trials
43 medical researchers
Summary
AdventHealth Orlando is a medical facility located in Orlando, Florida. This center is recognized for care of Cancer, Recurrence, Leukemia, Tumors, Non-Small Cell Lung Cancer and other specialties. AdventHealth Orlando is involved with conducting 658 clinical trials across 822 conditions. There are 43 research doctors associated with this hospital, such as Fouad M. Hajjar, Carlos Alemany, Mohamedtaki A. Tejani, and Ki Hyeong Lee.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Recurrence
Global LeaderStage IV
Stage III
Stage I
Top PIs
Fouad M. HajjarAdventHealth Orlando7 years of reported clinical research
Expert in Tumors
Expert in Brain Tumor
40 reported clinical trials
81 drugs studied
Carlos AlemanyAdventHealth Orlando4 years of reported clinical research
Studies Breast Cancer
Studies Cancer
21 reported clinical trials
58 drugs studied
Mohamedtaki A. TejaniAdventHealth Orlando2 years of reported clinical research
Studies Adenocarcinoma
Studies Colorectal Cancer
17 reported clinical trials
35 drugs studied
Ki Hyeong LeeChungbuk National University Hospital1 year of reported clinical research
Expert in Non-Small Cell Lung Cancer
Studies Lung Cancer
15 reported clinical trials
23 drugs studied
Clinical Trials running at AdventHealth Orlando
Non-Small Cell Lung Cancer
Breast Cancer
Cancer
Ovarian Tumors
Acute Lymphoblastic Leukemia
Non-Hodgkin's Lymphoma
Graft-versus-Host Disease
Lung Cancer
Colorectal Cancer
Lymphoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
BAY2862789
for Non-Small Cell Lung Cancer
Researchers are looking for a better way to treat people who have advanced solid tumors including a specific kind of lung cancer (non-small cell lung cancer, NSCLC). Advanced solid tumors are types of cancer that have spread to nearby tissue, lymph nodes, and/or to distant parts of the body and that are unlikely to be cured or controlled with currently available treatments. BAY2862789 works by blocking an enzyme in T-cells, thereby activating them. T-cells are a type of immune cell that are known to have an anti-cancer effect. The main purpose of this first-in-human study is to learn: * how safe different doses of BAY2862789 are, * the degree to which medical problems caused by BAY2862789 can be tolerated (also called tolerability), * what maximum amount (dose) can be given, and * how BAY2862789 moves into, through and out of the body. To answer this, the researchers will look at: * the number and severity of medical problems participants have after taking BAY2862789 for each dose level. These medical problems are also referred to as adverse events. An adverse event is considered "serious" when it leads to death, puts the participants' lives at risk, requires hospitalization, causes disability, causes a baby being born with medical problems or is otherwise medically important. * the (average) total level of BAY2862789 in the blood (also called AUC) after intake of single and multiple doses. * the (average) highest level of BAY2862789 in the blood (also called Cmax) after intake of single and multiple doses. Doctors and their team keep track of all medical problems that participants have during the study, even if they do not think the medical problem might be related to the study treatment. In addition, the researchers want to know if and how the participants' tumors change after taking BAY2862789. The study will have two parts. The first part, called dose escalation, is done to find the most appropriate dose that can be given in the second part of the study. For this, each participant will receive one of the increasing doses of BAY2862789. All participants in the second part of the study, called dose expansion, will receive the most appropriate dose identified from the first part of the study, as tablet by mouth. Participants in both parts of the study, will take the study treatment until their tumor gets worse (also known as 'disease progression'), until they have medical problems, until they leave the study, or until the study is terminated. Each participant will be in the study for several months, including a test (screening) phase of up to 28 days, few months of treatment depending on the participant's benefit, and a follow up phase after the end of treatment. The following approximate numbers of visits to the study site are planned: two during the screening phase, six in the first treatment month, one to three per month in the following periods. During the study, the study team will: * take blood and urine samples * do physical examinations * check vital signs such as blood pressure, heart rate, body temperature * examine heart health using ECG (electrocardiogram) * check cancer status using CT (computed tomography) or MRI (magnetic resonance imaging) and, if needed, bone scans * take tumor samples (if required) * pregnancy test The treatment period ends with a visit no later than 7 days after the last BAY2862789 dose. The study doctors and their team will check the participants' health and any changes in cancer about 30 and 90 days after the last dose and every 12 weeks thereafter. This follow-up period ends if the cancer worsens, if a new anti-cancer treatment is started, or until the participant leaves the study. In addition, the study doctors and their team will contact the participant every 12 weeks to learn about the participant's survival. This ends no later than 12 months after the last participant started treatment or by the end of the study, whichever comes first. If the study participant benefits from treatment, continuation of treatment with BAY2862789 beyond the duration of this study might be possible.
Recruiting1 award Phase 112 criteria
Amivantamab
for Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation \[SC-CF\]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Recruiting1 award Phase 219 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at AdventHealth Orlando?
AdventHealth Orlando is a medical facility located in Orlando, Florida. This center is recognized for care of Cancer, Recurrence, Leukemia, Tumors, Non-Small Cell Lung Cancer and other specialties. AdventHealth Orlando is involved with conducting 658 clinical trials across 822 conditions. There are 43 research doctors associated with this hospital, such as Fouad M. Hajjar, Carlos Alemany, Mohamedtaki A. Tejani, and Ki Hyeong Lee.
Where is AdventHealth Orlando located?
**AdventHealth Orlando**
- **Address:** 601 E Rollins St, Orlando, FL 32803
- **Location:** Conveniently located near downtown Orlando, close to major highways and public transportation options.
- **Parking:** Free garage parking available; valet service offered for a fee.
Who should I call to ask about financial aid or insurance network?
For financial assistance at AdventHealth Orlando, please call 407-303-5600. For inquiries about the application process, contact the financial counseling department at 844-652-0600. Further information is available by selecting a specific location on the AdventHealth website.
What insurance does AdventHealth Orlando accept?
AdventHealth Orlando accepts a wide range of insurance plans, including, but not limited to, Aetna, AvMed, Blue Cross & Blue Shield of Florida, Cigna, Humana, and Molina Healthcare of Florida. Coverage types include HMO, PPO, Medicaid, Medicare, and Work Comp. It's recommended to call in advance to confirm if your plan is accepted.
What awards or recognition has AdventHealth Orlando received?
AdventHealth Orlando, located in Orlando, Florida, is renowned for its exceptional research and care, earning numerous accolades. It is accredited as a Community Comprehensive Cancer Center by the American College of Surgeons Commission on Cancer and recognized for quality and innovation by the American Society of Clinical Oncology. The AdventHealth Research Institute leads in research, conducting over 690 studies in 2021, and maintains partnerships with prestigious organizations such as the National Cancer Institute, Duke Oncology Network, and Sarah Cannon Oncology Research Consortium.